We bring science, determination, and compassion to bear on diseases and conditions that have long vexed humanity.
A Legacy of Research & Discovery
For more than 75 years, UT Southwestern has brought together the brightest minds in science and medicine to promote health and a healthy society. Their groundbreaking discoveries have revealed the biology behind common diseases, allowing pharmaceutical companies to develop therapies that enhance the health of millions worldwide.
6 Nobel Prizes in the last 35+ years:
- Two for Cholesterol Regulation
- Membrane Protein Structure
- Cell Signaling
- Innate Immunity
- Synapses and Neural Function
The Nobel Prize-winning research of Michael Brown and Joseph Goldstein on the underlying mechanism of cholesterol metabolism explained the LDL-lowering action of statin drugs, one of the most widely prescribed medications in the world. Their discovery reduced the risk of heart disease and stroke for millions of people.
The pioneering Dallas Heart Study launched by Helen Hobbs and Jonathan Cohen provided invaluable findings that led to a new class of drugs called PCSK9 inhibitors. Clinical studies have shown these drugs dramatically lower LDL cholesterol levels and reduce heart attacks.
5-Alpha Reductase Inhibitors
Jean Wilson’s research revealed that prostate enlargement and male balding occur when too much DHT (dihydrotestosterone) is produced. David Russell’s team discovered key genes critical to turning testosterone into DHT. Together, their research led to 5-alpha reductase inhibitors, widely prescribed to treat enlarged prostate and balding in men.
Endothelin Receptor Blockers
Pulmonary hypertension is high blood pressure in the lungs. Masashi Yanagisawa discovered endothelin, a protein that constricts blood vessels. His findings led to endothelial receptor blockers that reduce lung blood pressure and restore a measure of health.
Orexin Receptor Blockers
Masashi Yanagisawa discovered orexin, a chemical produced in the brain that keeps people awake. This led to orexin receptor blockers that treat insomnia by inducing restful sleep.
1,000+ Clinical Trials
are currently underway at UT Southwestern.